Perflubutane

全氟丁烷

Report date: 2024/11/28 10:26:23
NME

Base Information

Drug NamePerflubutane
Drug Alias NameSonazoidDD-723DD-723-BNC-100100NUS
ClassificationSmall moleculesDiagnostic agent (In vivo) > Contrast agent
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsRejection of renal transplantationContrast agentsSkin Melanoma +[17] 
Global Approved IndicationsContrast agents
Approved Indications in ChinaContrast agents
Original Approved Country/TerritoryJapan
Original Approved Date2006/10/20
Country/TerritoryUnited StatesTaiwanNetherlands +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesDaiichi Sankyo Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesThe Brigham and Women's HospitalThe Netherlands Cancer InstituteSidney Kimmel Cancer Center At Thomas Jefferson University +[5] 
Inactive CompaniesOregon Health And Science UniversityAcusphere IncGe Healthcare +[5] 
Active IndicationsRejection of renal transplantationContrast agentsHeart Failure +[11] 
Inactive IndicationsSkin MelanomaPeripheral Arterial DiseaseCoronary Artery Disease +[6] 

Other Information

ATC CodeV09
Related LinksWikipediaDrugBankKEGG